The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer—the most common form of breast cancer in Australia—according to preclinical studies led by Walter ...
May 7, 2020
0
260
Until now, there has been no adequate treatment available for the rare and highly aggressive malignant blood disease T-PLL leukaemia. By screening blood samples from patients with haematological diseases, a team of doctors ...
Oct 24, 2017
0
19
A new editorial paper titled "Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability" has been published in Oncotarget.
Jun 28, 2023
0
2
An existing blood cancer drug has shown promise in killing "silent" HIV cells in animal models and human cells from people living with HIV—a significant pre-clinical discovery that could lead to a cure for the disease.
Aug 31, 2023
0
21
Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.
Nov 29, 2018
0
4
Chemotherapy has been the most effective treatment to date for young and fit patients with chronic lymphocytic leukemia (CLL). The disease is the most common form of leukemia in the Western world, causing a substantial health ...
May 10, 2023
0
43
Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood, and can quickly cause death if not treated promptly. Despite recent therapeutic advances, it continues ...
Feb 7, 2023
0
22
(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.
May 17, 2019
0
1
Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of ...
Feb 23, 2023
0
38
Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), ...
Aug 15, 2016
0
4
